Details for Patent: 7,304,078

Which drugs does patent 7,304,078 protect, and when does it expire?

Patent 7,304,078 protects ZONTIVITY and is included in one NDA.

This patent has one hundred and sixty-four patent family members in thirty-seven countries.

Summary for Patent: 7,304,078

Title:	Thrombin receptor antagonists
Abstract:	Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt thereof, wherein:
Inventor(s):	Samuel Chackalamannil, William J. Greenlee, Yuguang Wang, Wenxue Wu, Enrico P. Veltri, Yan Xia
Assignee:	Deerfield Management Company Lp As Administrative Agent , Xspire Pharma LLC
Application Number:	US10/412,982
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 7,304,078

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Key Therap	ZONTIVITY	vorapaxar sulfate	TABLET;ORAL	204886-001	May 8, 2014		DISCN	Yes	No	7,304,078		Y	Y		REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS

International Family Members for US Patent 7,304,078

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1495018		C300746	Netherlands
European Patent Office	1495018		CA 2015 00037	Denmark
European Patent Office	1495018		PA2015027	Lithuania
European Patent Office	1495018		C20150025 00159	Estonia
European Patent Office	1495018		CR 2015 00037	Denmark